PDO MAX INC, a medical device provider for medical aesthetic needs in the United States and Canadian markets, has received 510(k) approval from the US Food and Drug Administration (FDA) for its brand of PDO (polydioxanone) absorbable threads in cannula, it was reported on Friday.
PDO threads are utilised in aesthetic medicine and are a sterile, biodegradable, monofilament synthetic composed polymer. The approval is for both the PDO threads and cannula integrated into one device, unlike many of the other providers in the market.
Juliana Ucchino, vice president of Operations for PDO Max Inc, said, 'We are dedicated to bringing our aesthetic medical professionals, true peace of mind with our FDA cleared PDO threads. PDO MAX threads, used alone, or in addition to the provider's preferred injectable product, greatly add to the ability of our medical professionals to deliver nonsurgical, minimally invasive total facial aesthetics solutions.'
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder
Kedrion to be honoured at Premier's Supplier Innovation Celebration
Zydus and MSN announce US launch of generic Adempas (Riociguat Tablets)
FDA approves second Reykjavik manufacturing suite for AVT02
Ractigen Therapeutics reports positive first-in-human data for RAG-18 in Duchenne muscular dystrophy
AnnJi Pharmaceutical's AJ201 advances into pivotal Phase 3 trial for SBMA
Teva reports new ecopipam data showing tic reduction in Tourette syndrome